Day: April 21, 2020

Rotterdam, the Netherlands, 21 April 2020The Annual General Meeting of Koninklijke Vopak N.V. (Royal Vopak) held on 21 April 2020 passed the following resolutions:Approval implementation remuneration policy for the 2019 financial year.Adoption of the financial statements for the 2019 financial year.Approval of the proposed dividend. A dividend of EUR 1.15 per ordinary share with a nominal value of EUR 0.50 will be distributed wholly in cash on 29 April 2020. As from 23  April 2020, the shares of Vopak will be listed ex-dividend on Euronext Amsterdam.Discharge from liability of the Executive Board members’ conduct of the company’s affairs for the 2019 financial year.  Discharge from liability of the Supervisory Board members’ supervision exercised for the 2019 financial year.Appointment of Mr. B.J. Noteboom (Ben) as a member of the Supervisory...

FORESIGHT VCT PLC (Company)Increase in Offer SharesThe Company issued a prospectus dated 28 January 2020 (Prospectus) relating to an offer for subscription to raise up to £20 million, with an over-allotment facility to raise up to a further £5 million (Offer), through the issue of ordinary shares of 1p each in the capital of the Company (Offer Shares). The Company announced utilisation of the over-allotment facility on 13 March 2020.The Company announces an increase to the maximum number of Offer Shares available under the Offer from 32.5 million to 34.5 million (Increase). The increase is to accommodate the additional number of Offer Shares required to raise the aggregate amount of £25 million originally sought under the Offer as a result of Offer Shares being issued at the lower NAV per Share announced on 27 March 2020, which reflected...

LUBBOCK, Texas, April 21, 2020 (GLOBE NEWSWIRE) — South Plains Financial, Inc. (NASDAQ:SPFI) (“South Plains” or the “Company”), the parent company of City Bank, today announced that its first quarter 2020 financial results will be released after market close on Thursday, April 30, 2020.  The Company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the financial results.Investors and analysts interested in participating in the call are invited to dial 1-800-347-6311 (international callers please dial 1-646-828-8143) approximately 10 minutes prior to the start of the call.  A live audio webcast of the conference call will be available on the Company’s website at https://www.spfi.bank/news-events/events. A replay of the conference call will be available within two hours of the conclusion...

Philadelphia, PA, April 21, 2020 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC:VSBGF) (“VSBLTY”), a leading retail software technology company, and Photon-X, developers of sensor technologies that enable biometric verification, document security, CGI motion imaging and photo mapping, today jointly announced a collaboration to develop advanced camera applications to help screen for persons who may be infected with COVID-19 as they enter buildings.The two firms are collaborating to develop a multi-sensor camera capability specifically for security and smart buildings applications. Photon-X object recognition and analytics combined with VSBLTY facial recognition will provide an advanced screening tool for facilities to identify and validate that someone with a high temperature is about to enter...

TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA has approved a budget of approximately $1.8 million for the VB-111 project during 2020, with 50% of this amount as an IIA grant. The funds will support the continued development of VBL’s lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. VB-111 is currently being evaluated in a Phase 3 potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer.On March 26, 2020, VBL announced a positive outcome in the first interim analysis in the OVAL study, demonstrating an absolute percentage advantage...

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR SWITZERLAND Press ReleaseRegulated Information 21 April 2020, 1:00pm, Antwerp (Berchem), Belgium: VGP NV (‘VGP’ or ‘the company’), a leading European provider of high-quality logistics and semi-industrial real estate, announces the following:VGP is launching a capital increase in cash by means of a private placement via an accelerated bookbuild offering with international institutional investors (the ‘Capital Increase’)The targeted amount of the Capital Increase is gross proceeds of approximately € 200 millionThe accelerated bookbuild procedure will start immediately after publication of this press releaseVGP has requested that trading of VGP shares on the Euronext Brussels and Prague Stock Exchange regulated markets be suspended until the results...

NIET VOOR DISTRIBUTIE IN OF NAAR DE VERENIGDE STATEN VAN AMERIKA, JAPAN, CANADA, AUSTRALIË OF ZWITSERLANDPersberichtGereglementeerde informatie21 april 2020, 13:00, Antwerpen (Berchem), België: VGP NV (‘VGP’ of ‘de Vennootschap’), een toonaangevende pan-Europese ontwikkelaar, beheerder en eigenaar van hoogwaardig logistiek en semi-industrieel vastgoed, kondigt het volgende aan:VGP lanceert een kapitaalverhoging in geld door middel van een versnelde vrijgestelde private plaatsing bij institutionele beleggers (de ‘Kapitaalverhoging’)Het beoogde bruto bedrag van de Kapitaalverhoging is circa € 200 miljoenDe versnelde private plaatsing (accelerated bookbuild) zal starten onmiddellijk na publicatie van dit persberichtVGP heeft verzocht de verhandeling in VGP-aandelen op de gereglementeerde markten van Euronext Brussels en de Prague Stock Exchange...

SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the first quarter 2020 after the close of trading on Thursday, April 30, 2020. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.Individuals interested in listening to the conference call may do so by dialing 877-300-8521 for domestic callers or 412-317-6026 for international callers. Please reference Conference ID: 10142794. To listen to a live webcast, please visit...